TheraRadar
Data updated: Jun 17, 2026

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (calcium chloride)

Other Approved 1985-04-05

This intravenous solution is indicated as a source of water, electrolytes, and calories in both adult and pediatric patients. It is used for the maintenance and replacement of extracellular fluid and to provide metabolic energy. By combining essential electrolytes with dextrose, the solution supports osmotic pressure, acid-base balance, and prevents the depletion of glycogen stores.

Source: FDA Label • OTSUKA ICU MEDCL

How POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER Works

This medication functions as a parenteral source of hydration, electrolytes, and energy. **Dextrose** provides calories, reduces catabolism of body protein, and spares glycogen stores. **Sodium** regulates water distribution and osmotic pressure, while **Potassium** is critical for nerve conduction and cardiac muscle contraction. **Chloride** maintains the acid-base equilibrium. **Calcium** is essential for blood coagulation, bone integrity, and neuromuscular function. The **Lactate** component (in the Lactated Ringer's base) is metabolized to bicarbonate, acting as an alkalizing agent to help regulate systemic pH.

2
Indications
--
Phase 3 Trials
41
Years on Market

Details

Status
Discontinued
First Approved
1985-04-05
Routes
INJECTION
Dosage Forms
INJECTABLE

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER Approval History

1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
36 FDA actions from 1985 to 2025
Nov 2025 SUPPL
Label · Labeling
Oct 2019 SUPPL
Label · Labeling
Dec 2017 SUPPL
Label · Labeling

What POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER Treats

2 indications

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER is approved for 2 conditions since its original approval in 1985. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Electrolyte imbalance
  • Dehydration
Source: FDA Label

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 2 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

3 of 7

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMPHADASE
HYALURONIDASE
1 shared
AMPHASTAR PHARM
Shared indications:
Dehydration
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER
CALCIUM CHLORIDE
1 shared
Fresenius Kabi
Shared indications:
Dehydration
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER
CALCIUM CHLORIDE
1 shared
Fresenius Kabi
Shared indications:
Dehydration
📋

Clinical Trial Registry

7 trials
Trial Sponsor ID Phase Status Title
NCT07550413 20042026 Ph 2 not yet recruiting Role of Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Section
NCT03772990 ICARUS 21/2019 Ph 4 completed Calcium Administration in Cardiac Surgery
NCT05027048 CALBLOC results posted 62206 MRTG-02-15-2022-Ansari, YIG-2020 Ph 3 completed Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
NCT04153435 COCA results posted 00002 2019-003387-46 Ph 2 completed Calcium for Out-of-Hospital Cardiac Arrest
NCT03867383 results posted 43076 Ph 1, Ph 2 completed Calcium Chloride for Prevention of Uterine Atony During Cesarean
NCT01941914 AA1310 Ph 1 completed Calcium Electroporation for the Treatment of Keloids
NCT00955266 results posted 2009-P-000052 Ph 4 terminated A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER FDA Label Details

Indications & Usage

FDA Label (PDF)

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER is indicated for the treatment of Electrolyte imbalance; Dehydration.

Track POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.